VGVictoria Garcia-Ruiz

Victoria Garcia-Ruiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Victoria Garcia-Ruiz has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Continuous Glucose Monitoring Trajectories in Patients with Acute Coronary Syndrome

    by Arancha Díaz Expósito, Victoria García-Ruiz, Diego Castillo-Barnes, Andres Ortiz, Jose Ignacio Larrubia-Valle, Agustín Molinero, Fernando Puyol-Ruiz, Oscar Barquero-Alegre, Nelsa González-Aguayo, Laura Martin-Chaves, et al.

    Background Continuous glucose monitoring (CGM) captures dysglycaemia and glycaemic variability after acute coronary syndrome (ACS), but patient-level trajectories from early recovery to mid-term follow-up—particularly in people without diabetes—remain insufficiently characterised. Methods In this prospective multicentre observational study (ORACLE programme), consecutive high-risk ACS patients wore a FreeStyle Libre 3/3 Plus sensor for 14–15 days near discharge and again at ~ 4 months. We quantified CGM time-in-range metrics (70–180 mg/dL and tight range 70–140 mg/dL), time above/below range, and variability/risk indices, including within-day profiles. Clinically relevant changes were categorised using pre-specified thresholds, and predictors of worsening were explored using multivariable models. Results Among 274 enrolled patients, 213 had analyzable baseline CGM recordings meeting quality criteria. Early post-ACS mean time-in-range 70–180 was 85.7 ± 21.4%, time in tight range 70–140 was 69.6 ± 27.7%, time above range > 180 was 12.8 ± 21.5%, and time below range < 70 was 1.5 ± 3.3% (mean glucose 131.4 ± 35.6 mg/dL; glucose management indicator 6.4 ± 0.8%). CGM demonstrated marked inter-individual heterogeneity and a reproducible late-morning (10:00–12:00) vulnerability window with lower range time and higher hyperglycaemic exposure, consistent across diabetes status and similar on weekdays and weekends; adverse CGM profiles were more prominent in patients with diabetes, older individuals, and women. Although CGM parameters improved modestly over the initial monitoring period, overall control deteriorated from baseline to ~ 4 months, including in patients without diabetes. Tight-range time decreased by 3.8% (95% CI − 6.67 to − 0.99; p = 0.0077) and mean glucose increased by 3.85 mg/dL (p = 0.035), accompanied by worsening variability and risk indices. Across CGM endpoints, ~ 20–40% of patients showed a worsening trajectory (20.2% by broad time-in-range thresholds); higher comorbidity burden clustered with deterioration, with hypertension and COPD independently associated with tight-range worsening. Conclusions After ACS, CGM reveals substantial inter-individual heterogeneity and a reproducible late-morning vulnerability window. From discharge to mid-term follow-up, deterioration—also affecting patients without diabetes—may be preferentially detected by tight-range and variability/risk metrics that traditional monitoring of blood glucose and static measures such as HbA1c may overlook, supporting CGM-informed phenotyping to refine post-ACS metabolic surveillance.

  • Open Access

    Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

    by Francesco Pallante, Francesco Costa, Victoria Garcia Ruiz, Giampiero Vizzari, Pietro Iannello, Lucio Teresi, Gabriele Carciotto, Stefania Lo Giudice, Giustina Iuvara, Giulia Laterra, et al.

    Transcatheter aortic valve implantation (TAVI) now represents the mainstay of treatment for severe aortic stenosis. Owing to its exceptional procedural efficacy and safety, TAVI has been extended to include patients at lower surgical risk, thus now encompassing a diverse patient population receiving this treatment. Yet, long-term outcomes also depend on optimal medical therapy for secondary vascular prevention, with antithrombotic therapy serving as the cornerstone. Leveraging data from multiple randomized controlled trials, the current guidelines generally recommend single antithrombotic therapy, with either single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) alone in those patients without or with atrial fibrillation, respectively. Yet, individualization of this pattern, as well as specific case uses, may be needed based on individual patient characteristics and concurrent procedures. This review aims to discuss the evidence supporting antithrombotic treatments in patients treated with TAVI, indications for a standardized treatment, as well as specific considerations for an individualized approach to treatment.


  • Open Access

    Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

    by Francesco Pallante, Francesco Costa, Victoria Garcia Ruiz, Giampiero Vizzari, Pietro Iannello, Lucio Teresi, Gabriele Carciotto, Stefania Lo Giudice, Giustina Iuvara, Giulia Laterra, et al.

    Transcatheter Aortic Valve Implantation (TAVI) now represents the mainstay in the treatment of severe aortic stenosis. Owing to its exceptional procedural efficacy and safety, TAVI has been extended to include patients at lower surgical risk, thus now encompassing a diverse patient population receiving this treatment. Yet, long-term outcomes also depend on optimal medical therapy for secondary vascular prevention, with antithrombotic therapy serving as a cornerstone. Leveraging data from multiple randomized controlled trials, current guidelines generally recommend single antithrombotic therapy, with either single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) alone in those patients without, or with atrial fibrillation respectively. Yet, individualization of this pattern, as well as specific case uses, may be needed based on individual-patient characteristics and concurrent procedures. This review aims to discuss the evidence supporting antithrombotic treatments in patients treated with TAVI, indications for a standardized treatment, as well as specific considerations for an individualized approach to treatment.


  • Open Access

    The Evolving Field of Acute Coronary Syndrome Management: A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome

    by Roberto Licordari, Francesco Costa, Victoria Garcia-Ruiz, Mamas A. Mamas, Guillaume Marquis-Gravel, Jose M. de la Torre Hernandez, Juan Jose Gomez Doblas, Manuel Jimenez-Navarro, Jorge Rodriguez-Capitan, Cristobal Urbano-Carrillo, et al.

    Acute coronary syndromes (ACS), encompassing conditions like ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndromes (NSTE-ACS), represent a significant challenge in cardiovascular care due to their complex pathophysiology and substantial impact on morbidity and mortality. The 2023 European Society of Cardiology (ESC) guidelines for ACS management introduce several updates in key areas such as invasive treatment timing in NSTE-ACS, pre-treatment strategies, approaches to multivessel disease, and the use of imaging modalities including computed tomography (CT) coronary angiography, magnetic resonance imaging (MRI), and intracoronary imaging techniques, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS). They also address a modulation of antiplatelet therapy, taking into consideration different patient risk profiles, and introduce new recommendations for low-dose colchicine. These guidelines provide important evidence-based updates in practice, reflecting an evolution in the understanding and management of ACS, yet some potentially missed opportunities for more personalized care and technology adoption are discussed.


  • Open Access

    Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

    by Felice Gragnano, Antonio Capolongo, Antonio Micari, Francesco Costa, Victoria Garcia-Ruiz, Vincenzo De Sio, Fabrizia Terracciano, Arturo Cesaro, Elisabetta Moscarella, Silvio Coletta, et al.

    The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC), provides anti-ischemic protection but increases the risk of bleeding. Therefore, TAT is generally limited to a short phase (1 week) after PCI, followed by aspirin withdrawal and continuation of 6–12 months of dual antithrombotic therapy (DAT), comprising OAC plus clopidogrel, followed by OAC alone. This pharmacological approach has been shown to mitigate bleeding risk while preserving adequate anti-ischemic efficacy. However, the decision-making process remains complex in elderly patients and those with co-morbidities, significantly influencing ischemic and bleeding risk. In this review, we discuss the available evidence in this area from randomized clinical trials and meta-analyses for post-procedural antithrombotic therapies in patients with non-valvular AF undergoing PCI.


  • Open Access

    Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation

    by Francesca Lofrumento, Natasha Irrera, Roberto Licordari, Silvia Perfetti, Enrica Nasso, Paolo Liotta, Giovanni Isgrò, Victoria Garcia-Ruiz, Francesco Squadrito, Scipione Carerj, et al.

    Several studies have demonstrated that, beyond their antithrombotic effects, P2Y12 receptor inhibitors may provide additional off-target effects through different mechanisms. These effects range from the preservation of endothelial barrier function to the modulation of inflammation or stabilization of atherosclerotic plaques, with an impact on different cell types, including endothelial and immune cells. Many P2Y12 inhibitors have been developed, from ticlopidine, the first thienopyridine, to the more potent non-thienopyridine derivatives such as ticagrelor which may promote cardioprotective effects following myocardial infarction (MI) by inhibiting adenosine reuptake through sodium-independent equilibrative nucleoside transporter 1 (ENT1). Adenosine may affect different molecular pathways involved in cardiac fibrosis, such as the Wnt (wingless-type)/beta (β)-catenin signaling. An early pro-fibrotic response of the epicardium and activation of cardiac fibroblasts with the involvement of Wnt1 (wingless-type family member 1)/β-catenin, are critically required for preserving cardiac function after acute ischemic cardiac injury. This review discusses molecular signaling pathways involved in cardiac fibrosis post MI, focusing on the Wnt/β-catenin pathway, and the off-target effect of P2Y12 receptor inhibition. A potential role of ticagrelor was speculated in the early modulation of cardiac fibrosis, thanks to its off-target effect.


  • Open Access

    Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review

    by Gabriele Carciotto, Francesco Costa, Victoria Garcia-Ruiz, Mattia Galli, Emmanuele Soraci, Alberto Magliarditi, Lucio Teresi, Enrica Nasso, Scipione Carerj, Gianluca Di Bella, et al.

    Dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 receptor inhibitor, is the cornerstone of post-percutaneous coronary intervention treatment to prevent stent thrombosis and reduce the risk of adverse cardiovascular events. The selection of an optimal DAPT regimen, considering the interplay of various antiplatelet agents, patient profiles, and procedural characteristics, remains an evolving challenge. Traditionally, a standard duration of 12 months has been recommended for DAPT in most patients. While contemporary guidelines provide general frameworks, DAPT modulation with longer or shorter treatment courses followed by aspirin or P2Y12 inhibitor monotherapy are evolving towards an individualized strategy to optimize the balance between efficacy and safety. This review comprehensively examines the current landscape of DAPT strategies after coronary stenting, with a focus on emerging evidence for treatment individualization.


  • Open Access

    Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based, Review

    by Gabriele Carciotto, Francesco Costa, Victoria Garcia-Ruiz, Mattia Galli, Emmanuele Soraci, Alberto Magliarditi, Lucio Teresi, Enrica Nasso, Scipione Carerj, Gianluca Di Bella, et al.

    Dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 receptor inhibitor, is the cornerstone of post-percutaneous coronary intervention treatment to prevent stent thrombosis and reduce the risk of adverse cardiovascular events. The selection of an optimal DAPT regimen, considering the interplay of various antiplatelet agents, patient profiles, and procedural characteristics, remains an evolving challenge. Traditionally, a standard duration of 12 months has been recommended for DAPT in most patients. While contemporary guidelines provide general frameworks, DAPT modulation with longer or shorter treatment courses followed by aspirin or P2Y12 inhibitor monotherapy are evolving towards an individualized strategy to optimize the balance between efficacy and safety. This review comprehensively examines the current landscape of DAPT strategies after coronary stenting, with a focus on emerging evidence for treatment individualization.


  • Open Access

    Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions

    by Alessandro Caracciolo, Paolo Mazzone, Giulia Laterra, Victoria Garcia-Ruiz, Alberto Polimeni, Salvatore Galasso, Francesco Saporito, Scipione Carerj, Fabrizio D’ascenzo, Guillaume Marquis-Gravel, et al.

    Percutaneous cardiovascular interventions have changed dramatically in recent years, and the impetus given by the rapid implementation of novel techniques and devices have been mirrored by a refinement of antithrombotic strategies for secondary prevention, which have been supported by a significant burden of evidence from clinical studies. In the current manuscript, we aim to provide a comprehensive, yet pragmatic, revision of the current available evidence regarding antithrombotic strategies in the domain of percutaneous cardiovascular interventions. We revise the evidence regarding antithrombotic therapy for secondary prevention in coronary artery disease and stent implantation, the complex interrelation between antiplatelet and anticoagulant therapy in patients undergoing percutaneous coronary intervention with concomitant atrial fibrillation, and finally focus on the novel developments in the secondary prevention after structural heart disease intervention. A special focus on treatment individualization is included to emphasize risk and benefits of each therapeutic strategy.


  • Open Access

    Radial Artery Access for Percutaneous Cardiovascular Interventions: Contemporary Insights and Novel Approaches

    by Renato Francesco Maria Scalise, Armando Mariano Salito, Alberto Polimeni, Victoria Garcia-Ruiz, Vittorio Virga, Pierpaolo Frigione, Giuseppe Andò, Carlo Tumscitz, Francesco Costa

    Since its introduction, the transradial access for percutaneous cardiovascular procedures has been associated with several advantages as compared to transfemoral approach, and has become the default for coronary angiography and intervention. In the last 30 years, a robust amount of evidence on the transradial approach has been mounted, promoting its diffusion worldwide. This article provides a comprehensive review of radial artery access for percutaneous cardiovascular interventions, including the evidence from clinical trials of transradial vs. transfemoral approach, technical considerations, access-site complications and limitations, alternative forearm accesses (e.g., ulnar and distal radial artery), and ultimately the use of the radial approach for structural interventions.